Sofosbuvir & Velpatasvir Tablets Manufacturer in India

Product Overview
Key Features
Therapeutic Uses
Dosage Form Advantages

Sofosbuvir & Velpatasvir Tablets are direct-acting antiviral medicines used for chronic hepatitis C treatment, viral suppression management, and pangenotypic HCV infection therapy across multiple hepatitis C genotypes.

The formulation contains Sofosbuvir, an NS5B polymerase inhibitor, and Velpatasvir, an NS5A inhibitor, which together interfere with hepatitis C viral replication and viral RNA synthesis pathways. The combination is widely utilized in antiviral treatment protocols aimed at controlling chronic HCV infection and supporting long-term liver health management.

Genliva Wellness LLP manufactures these formulations as a Sofosbuvir & Velpatasvir Tablets Manufacturer in India, supplying antiviral medicines for pharmaceutical distributors, institutional healthcare programs, government antiviral treatment initiatives, contract manufacturing services, and regulated international hepatitis care markets.

Sofosbuvir & Velpatasvir Tablets are formulated for hepatitis C antiviral therapy.

Direct-acting antiviral oral formulation
Frequently utilized in chronic hepatitis C treatment
Pangenotypic antiviral activity profile
NS5A and NS5B inhibitor combination
Manufactured using quality pharmaceutical ingredients
Intended for long-term antiviral treatment programs

This formulation is prescribed in hepatitis C management.

Treatment of chronic hepatitis C infection
Management of viral suppression therapies
Administered in genotype-inclusive HCV treatment
Utilized in long-term liver care protocols
Helps control hepatitis C viral replication
Frequently selected in antiviral treatment programs

Sofosbuvir & Velpatasvir Tablets deliver pangenotypic antiviral therapy for HCV management.

Valuable in chronic hepatitis C treatment
Frequently preferred in antiviral liver care programs
Broad genotype antiviral treatment support
Useful in long-term HCV management therapies
Convenient oral antiviral administration
Maintains reliable antiviral therapeutic performance